Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study

被引：0
|
作者：
Yang, James Chih-Hsin
Lee, Dae Ho
Lee, Jong-Seok
Fan, Yun
De Marinis, Filippo
Okamoto, Isamu
Inoue, Takako
Cid, Jeronimo Rafael Rodriguez
Zhang, Li
Yang, Cheng-Ta
Jimenez, Emmanuel De la Mora
Zhou, Jianying
Perol, Maurice
Lee, Hyeong
Lee, Ki Hyeong
Vicente, David
Ichihara, Eiki
Riely, Gregory J.
Luo, Yiwen
Bhagwati, Niyati Sanat
Lu, Shun
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[3] Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[6] Ist Europeo Oncol, Milan, Italy
[7] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan
[8] Osaka Int Canc Inst, Osaka, Japan
[9] Med Sur Hosp, Ctr Oncol, Mexico City, Mexico
[10] Peking Union Med Coll Hosp, Beijing, Peoples R China
[11] Chang Gung Mem Hosp, Taoyuan, Taiwan
[12] Inst Jalisciense Cancerol, Guadalajara, Mexico
[13] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Ctr Leon Berard, Lyon, France
[15] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[16] Hosp Univ Virgen Macarena, Seville, Spain
[17] Okayama Univ Hosp, Okayama, Japan
[18] Mem Sloan Kettering Canc Ctr, New York, NY USA
[19] Merck & Co Inc, Rahway, NJ USA
[20] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9000
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
    Elamin, Yasir Y.
    Gomez, Daniel R.
    Antonoff, Mara B.
    Robichaux, Jacqulyne P.
    Hai Tran
    Shorter, Melissa K.
    Bohac, Jadi M.
    Negrao, Marcelo Vailati
    Le, Xiuning
    Rinsurogkawong, Waree
    Lewis, Jeff
    Lacerda, Lara
    Roarty, Emily B.
    Swisher, Stephen G.
    Roth, Jack A.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki
    Heymach, John, V
    CLINICAL LUNG CANCER, 2019, 20 (01) : 43 - 47
  • [42] Preliminary Phase 1 Results of U3-1402-A Novel HER3-Targeted Antibody-Drug Conjugate-in EGFR TKI-Resistant, EGFR-Mutant NSCLC
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Chen, S.
    Kamai, Y.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S336 - S337
  • [43] A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
    Meijuan Huang
    Yongmei Liu
    Min Yu
    Yanying Li
    Yan Zhang
    Jiang Zhu
    Li Li
    You Lu
    Investigational New Drugs, 2022, 40 : 308 - 313
  • [44] A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
    Huang, Meijuan
    Liu, Yongmei
    Yu, Min
    Li, Yanying
    Zhang, Yan
    Zhu, Jiang
    Li, Li
    Lu, You
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 308 - 313
  • [45] Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
    Borghaei, H.
    Langer, C. J.
    Gadgeel, S.
    Papadimitrakopoulou, V. A.
    Patnaik, A.
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Jalal, S. I.
    Panwalkar, A.
    Yang, J. C-H.
    Gubens, M.
    Sequist, L.
    Awad, M. M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    CANCER RESEARCH, 2019, 79 (13)
  • [47] A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.
    Bar, Jair
    Botser, Dana
    Navon, Rossie
    Peled, Nir
    Biran, Haim
    Gal-Yam, Einav Nili
    Ben-Arieh, Sayeh
    Raskin, Stephen
    Onn, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Janne, Pasi A.
    Yu, Helena Alexandra
    Johnson, Melissa Lynne
    Vigliotti, Michele
    Shipitofsky, Nicole
    Guevara, Ferdinand Morales
    Chen, Shuquan
    Yu, Channing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Vigliotti, M.
    Shipitofsky, N.
    Singh, J.
    Guevara, F.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2290 - S2290
  • [50] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Shipitofsky, N.
    Guevara, F. M.
    Chen, S.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S816
12345